Cancer Research

Genetics Might Explain Why Schizophrenics Have Lower Cancer Rates

A series of studies presented today at the American College of Neuropsychopharmacology (ACNP) annual meeting elucidates evidence that there is a genetic link between schizophrenia and cancer, providing a surprising possible scientific explanation for lower ...

Article - News Staff - Dec 8 2007 - 11:13am

SMCT1 And SMCT2 Transporters May Help Delay Retinal Damage From Diabetes

Two transporters that deliver alternative energy sources to the eye may help delay retinal damage that can occur in diabetes, researchers say. The transporters, SMCT1 and SMCT2, can circumvent the eye’s protective blood-retinal barrier, delivering energy s ...

Article - News Staff - Dec 8 2007 - 9:33pm

Pharmion Presents Clinical Data Demonstrating Significant Survival Advantage Of Azacitidine (Vidaza(R)) In Patients With Myelody

ATLANTA, Georgia, December 9 /PRNewswire/--- Data Demonstrate 9.4 Month Median Overall Survival Benefit in Higher-risk MDS for Azacitidine Compared to Conventional Care Regimens (Log Rank p=0.0001)- Two Year Overall Survival Rate of 50.8% for Azacitidine ...

Article - Anna Ohlden - Dec 9 2007 - 8:30am

Sometimes Epigenetic Multistability Is Nature's Friend

One gene for pea pod color generates green pods while a variant of that gene gives rise to the yellow-pod phenotype, a feature that helped Gregor Mendel, the 19th century Austrian priest and scientist, first describe genetic inheritance. However, many mode ...

Article - News Staff - Dec 9 2007 - 1:35pm

EpiCept Releases New Data Demonstrating Prolonged Five-Year Leukemia-Free Survival For AML Patients Treated With Ceplene(TM) + I

TARRYTOWN, New York, December 10 /PRNewswire/--- First Drug Regimen Shown to Prevent AML Relapse EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today released new clinical data that demonstrate a durable improvement in leukemia-free survival ( ...

Article - Anna Ohlden - Dec 10 2007 - 12:30am

Roche To Announce New Breast Cancer Data Pointing To Better Survival Chances And Potential For Cure

BASEL, Switzerland, December 10 /PRNewswire/--- Phase II Results Suggest Avastin Can be Used in Curative Setting Date Experts attending the 30th San Antonio Breast Cancer Symposium (SABCS) December 13-16, will be amongst the first to hear new data that hi ...

Article - Anna Ohlden - Dec 10 2007 - 3:30am

ImmunoVaccine Technologies Inc. To Acquire Immunotope Inc.

HALIFAX, Canada, December 10 /PRNewswire/-- ImmunoVaccine Technologies Inc. (IVT), a Nova Scotia-based vaccine enhancement company, has signed a binding memorandum of understanding to acquire Immunotope Inc., a Pennsylvania-based biotechnology company dev ...

Article - Anna Ohlden - Dec 10 2007 - 10:30am

FDA Grants Resverlogix Approval To Commence A Phase 1 Clinical Trial For RVX-208

CALGARY, Canada, December 10 /PRNewswire/--- New Class of ApoA-I/HDL Drugs to Reverse Atherosclerosis Enters the Clinic Resverlogix Corp. ("Resverlogix") (TSX:RVX) announced today that it has received approval by the US Food and Drug Administrat ...

Article - Anna Ohlden - Dec 10 2007 - 10:30am

Oncolytics Biotech Inc. Announces Issuance Of 25th U.S. Patent

CALGARY, Canada, December 11 /PRNewswire/-- Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) ("Oncolytics") today announced that it has been granted U.S. Patent 7,306,902 entitled "Oncolytic Viruses as Phenotyping Agents for Neoplasms." ...

Article - Anna Ohlden - Dec 11 2007 - 7:30am

Once-Daily Exjade(R) Shown To Remove Toxic Iron From The Heart And Liver, According To Data Presented At ASH

FRIMLEY, England, December 12 /PRNewswire/--- Approximately 78% of Beta-thalassaemia Patients had Decreases in Cardiac Iron and 90% had Decreases in Liver Iron After Six Months, Interim Data Show(1)- Study in Sickle Cell Disease (SCD) Patients With Iron O ...

Article - Anna Ohlden - Dec 12 2007 - 3:30am